MAYNF (Mayne Pharma Group) ROE % Adjusted to Book Value : -13.85% (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Mayne Pharma Group ROE % Adjusted to Book Value?

Mayne Pharma Group's ROE % for the quarter that ended in Dec. 2024 was -11.08%. Mayne Pharma Group's PB Ratio for the quarter that ended in Dec. 2024 was 0.80. Mayne Pharma Group's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -13.85%.

Mayne Pharma Group ROE % Adjusted to Book Value Historical Data

The historical data trend for Mayne Pharma Group's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mayne Pharma Group ROE % Adjusted to Book Value Chart

Mayne Pharma Group Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-15.34

-32.60

-54.49

38.26

-39.27

Mayne Pharma Group Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															204.10	-96.20	-25.36	-50.88	-13.85

Competitive Comparison of Mayne Pharma Group's ROE % Adjusted to Book Value

For the Drug Manufacturers - General subindustry, Mayne Pharma Group's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mayne Pharma Group's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mayne Pharma Group's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Mayne Pharma Group's ROE % Adjusted to Book Value falls into.

Mayne Pharma Group ROE % Adjusted to Book Value Calculation

Mayne Pharma Group's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-31.81%	/	0.81
	=	-39.27%

Mayne Pharma Group's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-11.08%	/	0.80
	=	-13.85%

Mayne Pharma Group ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Mayne Pharma Group's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Mayne Pharma Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mayne Pharma Group Ltd (OTCPK:MAYNF) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

HG6:Germany MYX:Australia

Address

1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106

Website

http://www.maynepharma.com

Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.